SCHEMBL9039468

SCHEMBL9039468

CC(C)(COC(c1ccccc1)(c1ccccc1)c1ccccc1)C(=O)O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 1/20 0.44
CYP2C19 P33261 1/20 0.44
HIF1A Q16665 1/20 0.44
HDAC6 Q9UBN7 2/20 0.43
HDAC3 O15379 1/20 0.43
HDAC4 P56524 1/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC7 Q8WUI4 1/20 0.43
HDAC2 Q92769 1/20 0.43
HDAC10 Q969S8 1/20 0.43
HDAC11 Q96DB2 1/20 0.43
HDAC8 Q9BY41 1/20 0.43
HDAC9 Q9UKV0 1/20 0.43
HDAC5 Q9UQL6 1/20 0.43
CYP2C9 P11712 1/20 0.41
KMT2A Q03164 2/20 0.41
MAPT P10636 1/20 0.41
PPARA Q07869 4/20 0.41
KCNN4 O15554 1/20 0.40
ELANE P08246 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12151786 0.89 SLC6A11 (0.46) KIF11KMT2AMAPTPPARAMEN1
SCHEMBL28021468 0.86 KIF11 (0.42) KIF11CYP2C19HIF1AHDAC6HDAC3
SCHEMBL9041026 0.84 KCNN4 (0.53) KIF11CYP2C19HIF1AHDAC6HDAC3
SCHEMBL12149872 0.84 KIF11 (0.47) KIF11CYP2C19CYP2C9KMT2AMAPT
SCHEMBL28021471 0.81 KIF11 (0.44) KIF11CYP2C19HIF1AHDAC6HDAC3
SCHEMBL20295113 0.80 TSHR (0.41) KIF11CYP2C19HIF1AHDAC6HDAC3
SCHEMBL17410560 0.78 CHRM2 (0.42) KIF11CYP2C19HIF1AHDAC6HDAC3
SCHEMBL2512972 0.78 CHRM2 (0.39) KIF11CYP2C19HIF1AHDAC6HDAC3
SCHEMBL8850056 0.78 KIF11 (0.52) KIF11CYP2C19HIF1AKCNN4ELANE
SCHEMBL12151785 0.77 KCNN4 (0.45) KIF11KMT2AMAPTKCNN4MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250282803-A1 DIDEHYDRO-3'-DEOXY-4'-ETHYNYLTHYMIDINES AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS ROME THERAPEUTICS, INC. 2025-09-11 US disclosed
EP-4511381-A1 DIDEHYDRO-3'-DEOXY-4'-ETHYNYLTHYMIDINES AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS Rome Therapeutics, Inc. (US) 2025-02-26 EP disclosed
CN-119403815-A Didehydro-3 '-deoxy-4' -ethynyl thymidine and related compounds and their use in treating medical conditions 罗梅治疗股份有限公司 2025-02-07 CN disclosed
WO-2023205786-A1 DIDEHYDRO-3'-DEOXY-4'-ETHYNYLTHYMIDINES AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS ROME THERAPEUTICS, INC. (US) 2023-10-26 WO disclosed
EP-3559011-B1 ANTIVIRAL ESTER PRODRUGS OF TENOFOVIR MERCK SHARP & DOHME (US) 2022-04-13 EP disclosed
EP-3559011-B1 ANTIVIRAL ESTER PRODRUGS OF TENOFOVIR MERCK SHARP & DOHME (US) 2022-04-13 EP disclosed
CN-110099912-B Antiviral tenofovir aliphatic ester prodrug 默沙东公司 2021-10-15 CN disclosed
US-10519159-B2 Antiviral aliphatic ester prodrugs of tenofovir MERCK SHARP & DOHME CORP. (US) 2019-12-31 US disclosed
US-10519159-B2 Antiviral aliphatic ester prodrugs of tenofovir MERCK SHARP & DOHME CORP. (US) 2019-12-31 US disclosed
CN-110099912-A Antiviral tenofovir aliphatic ester prodrug 默沙东公司 2019-08-06 CN disclosed
US-20180179208-A1 ANTIVIRAL ALIPHATIC ESTER PRODRUGS OF TENOFOVIR MERCK SHARP & DOHME CORP. (US) 2018-06-28 US disclosed
US-20180179208-A1 ANTIVIRAL ALIPHATIC ESTER PRODRUGS OF TENOFOVIR MERCK SHARP & DOHME CORP. (US) 2018-06-28 US disclosed
US-20180179208-A1 ANTIVIRAL ALIPHATIC ESTER PRODRUGS OF TENOFOVIR MERCK SHARP & DOHME CORP. (US) 2018-06-28 US disclosed
WO-2018119013-A1 ANTIVIRAL ALIPHATIC ESTER PRODRUGS OF TENOFOVIR MERCK SHARP & DOHME CORP. (US) 2018-06-28 WO disclosed
EP-0535192-B1 NOVEL DNA GYRASE INHIBITORS, PROCESS FOR THEIR MANUFACTURE AND PHARMACEUTICAL PREPARATIONS CONTAINING SAME HOFFMANN LA ROCHE (CH) 1996-06-19 EP disclosed
US-5486466-A ENZYME INHIBITORS HOFFMANN-LA ROCHE INC. (US) 1996-01-23 US disclosed
US-5399741-A DNA gyrase inhibitors, process for their manufacture and pharmaceutical preparations containing same HOFFMANN-LA ROCHE INC. (US) 1995-03-21 US disclosed
US-5294609-A Microbiocides HOFFMANN-LAROCHE INC. (US) 1994-03-15 US disclosed
EP-0535192-A1 NOVEL DNA GYRASE INHIBITORS, PROCESS FOR THEIR MANUFACTURE AND PHARMACEUTICAL PREPARATIONS CONTAINING SAME. HOFFMANN LA ROCHE (CH) 1993-04-07 EP disclosed
WO-1992018490-A1 NOVEL DNA GYRASE INHIBITORS, PROCESS FOR THEIR MANUFACTURE AND PHARMACEUTICAL PREPARATIONS CONTAINING SAME F. HOFFMANN-LA ROCHE AG (CH) 1992-10-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10519159-B2 Antiviral aliphatic ester prodrugs of tenofovir TYMP, PNP, GART KIF11 4544/4885CYP2C19 113/4885HIF1A 2195/4885
US-20250282803-A1 DIDEHYDRO-3'-DEOXY-4'-ETHYNYLTHYMIDINES AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS DTYMK, DCK, POLK KIF11 2714/4885CYP2C19 762/4885HIF1A 378/4885
US-20180179208-A1 ANTIVIRAL ALIPHATIC ESTER PRODRUGS OF TENOFOVIR TYMP, PNP, GART KIF11 4576/4885CYP2C19 118/4885HIF1A 2115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.